Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.41 |
| ▸ | RORC | P51449 | 8/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26640996 | 0.86 | MAPKAPK2 (0.45) | MAPKAPK2RORCATRCYP17A1 | |
| SCHEMBL6491966 | 0.83 | MAPKAPK2 (0.47) | MAPKAPK2RORCATRS1PR3CYP17A1 | |
| SCHEMBL23580479 | 0.80 | MALT1 (0.42) | — | |
| SCHEMBL25397341 | 0.78 | MAPKAPK2 (0.36) | MAPKAPK2RORCATRCA12CA1 | |
| SCHEMBL15974461 | 0.77 | CYP17A1 (0.43) | RORCATRCYP17A1 | |
| SCHEMBL1894319 | 0.77 | NAMPT (0.44) | MAPKAPK2RORCATRCYP17A1 | |
| SCHEMBL1010435 | 0.77 | ATR (0.46) | MAPKAPK2RORCATRCYP17A1STK17B | |
| SCHEMBL27576232 | 0.77 | MAPKAPK2 (0.41) | MAPKAPK2RORCATRCYP17A1STK17B | |
| SCHEMBL6366962 | 0.76 | STAT3 (0.41) | MAPKAPK2RORCCA12CA1CA2 | |
| SCHEMBL27575374 | 0.74 | ATR (0.46) | MAPKAPK2ATRCYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| CN-1335847-A | Sulfonamide compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | MAPKAPK2 1363/4885RORC 2308/4885ATR 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.